Evaluation of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AB-101 in Healthy Volunteers and Patients with Chronic Hepatitis B Virus Infection

The primary objective of this study is to evaluate the **safety**, **tolerability**, **pharmacokinetics**, and **pharmacodynamics** of AB-101 following oral administration in both healthy individuals and subjects with **chronic hepatitis B virus infection**. This evaluation is clinically relevant as it aims to determine the potential therapeutic benefits and risks associated with AB-101, which could inform future treatment strategies for chronic hepatitis B, a condition that poses significant health challenges globally.

The clinical trial involves a total of **40 participants** diagnosed with **chronic hepatitis B virus infection**. The study population includes both male and female subjects, with an age range of 18 to 65 years. Participants were selected to include a vulnerable population, although specific criteria for vulnerability are not detailed. The trial does not specify particular lifestyle considerations such as diet or physical activity. The sponsor has not provided information regarding the main objective of the trial or the principal inclusion criteria. The selection process aimed to encompass a diverse group within the specified age range, ensuring representation across genders.

The clinical trial is designed to evaluate the **safety**, tolerability, pharmacokinetics, and pharmacodynamics of AB-101 following oral administration in both healthy subjects and those with **chronic hepatitis B virus infection**. This study is structured as a Phase 1 trial, which is typically the initial phase in clinical research focusing on assessing the safety profile of a new investigational drug. The trial is expected to commence recruitment on December 1, 2024, and is projected to conclude by January 1, 2027. The study employs a randomized, double-blind, controlled design to ensure unbiased results and to maintain the integrity of the data collected.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to determine eligibility based on predefined criteria. This initial visit will involve a comprehensive assessment to ensure that participants meet the necessary inclusion criteria and do not fall under any exclusion criteria. Following successful screening, participants will be randomized into different study arms. Throughout the trial, there will be scheduled follow-up visits to monitor the participants' health, assess the drug's pharmacokinetics and pharmacodynamics, and collect safety data. These visits are crucial for evaluating the ongoing effects of the drug and for making any necessary adjustments to the study protocol.

The end-of-study visit will mark the conclusion of a participant's involvement in the trial. During this visit, final assessments will be conducted to gather comprehensive data on the drug's impact and to ensure the well-being of the participants. The expected length of participant involvement will vary depending on the specific study arm and individual response to the treatment. Conditions that may lead to early termination from the study include adverse reactions to the investigational drug, non-compliance with study procedures, or withdrawal of consent by the participant. The trial's design and procedures are meticulously planned to ensure the collection of high-quality data while prioritizing participant safety and adherence to ethical standards.

The clinical trial documentation does not provide specific details regarding the **experimental medication** used in the study. Information such as the name, pharmaceutical form, dosage, route, and frequency of administration is not available. Additionally, there is no data on whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. The maximum daily dose, total dose, and treatment period are also unspecified.

Details about any **non-experimental treatments** used in the study, such as standard-of-care therapy, placebo, or comparator treatment, are not provided. There is no information on the administration of other medicinal products or their role in the trial.

Due to the lack of available data, further specifics on drug administration, dosing schedules, and participant compliance monitoring cannot be described. The absence of this information limits the ability to provide a comprehensive overview of the treatments involved in the clinical trial.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, which typically focuses on assessing safety, tolerability, and pharmacokinetics, but may also include preliminary efficacy assessments. The trial is scheduled to commence recruitment on December 1, 2024, with an estimated completion date of January 1, 2027. Although specific efficacy endpoints are not detailed, Phase 1 trials often utilize various parameters such as **biomarker** levels or symptom improvement scores to gather initial efficacy data. The methods and schedule for measuring, collecting, and analyzing these parameters are not specified, but they generally involve validated scales, laboratory tests, or patient-reported outcomes at predetermined timepoints. The trial will adhere to rigorous scientific standards to ensure the reliability and validity of the efficacy data collected.